kiniksa
reports
third
quarter
financial
results
highlights
recent
pipeline
corporate
activity
rilonacept
commercial
launch
recurrent
pericarditis
anticipated
approved
fda
mavrilimumab
phase
trial
gca
achieved
primary
secondary
efficacy
endpoints
statistical
significance
cohorts
dosed
phase
study
cash
reserves
approximately
million
expected
fund
current
operating
plan
hamilton
bermuda
globe
newswire
kiniksa
pharmaceuticals
nasdaq
knsa
kiniksa
biopharmaceutical
company
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
today
reported
third
quarter
financial
results
highlighted
recent
pipeline
corporate
activity
kiniksa
continues
execute
across
pipeline
said
sanj
patel
chief
executive
officer
chairman
board
kiniksa
preparing
commercial
launch
rilonacept
recurrent
pericarditis
first
half
approved
fda
primary
secondary
efficacy
endpoints
mavrilimumab
phase
trial
giant
cell
arteritis
achieved
statistical
significance
demonstrating
potential
broad
utility
molecule
additionally
cohorts
dosed
phase
study
program
expect
data
first
cohorts
pipeline
activity
rilonacept
cytokine
trap
kiniksa
anticipates
commercial
launch
rilonacept
recurrent
pericarditis
first
half
approved
food
drug
administration
fda
assuming
priority
review
rilonacept
approved
recurrent
pericarditis
fda
kiniksa
commence
sales
distribution
rilonacept
approved
indications
united
states
evenly
split
profits
sales
regeneron
pharmaceuticals
regeneron
obligated
pay
regulatory
milestones
regeneron
aggregate
million
potential
approval
rilonacept
recurrent
pericarditis
rilonacept
approved
recurrent
pericarditis
fda
kiniksa
commence
sales
distribution
rilonacept
approved
indications
united
states
evenly
split
profits
sales
regeneron
pharmaceuticals
regeneron
obligated
pay
regulatory
milestones
regeneron
aggregate
million
potential
approval
rilonacept
recurrent
pericarditis
kiniksa
expects
data
rhapsody
pivotal
phase
clinical
trial
rilonacept
recurrent
pericarditis
presented
science
session
american
heart
association
aha
scientific
sessions
allan
klein
md
cleveland
clinic
investigator
rhapsody
deliver
virtual
presentation
entitled
rhapsody
rilonacept
trap
resolves
pericarditis
episodes
reduces
risk
recurrence
phase
trial
patients
recurrent
pericarditis
monday
november
central
time
mavrilimumab
monoclonal
antibody
inhibitor
targeting
kiniksa
recently
announced
positive
data
global
phase
clinical
trial
mavrilimumab
giant
cell
arteritis
gca
primary
efficacy
endpoint
adjudicated
gca
flare
week
treated
patients
hazard
ratio
secondary
efficacy
endpoint
sustained
remission
week
treated
patients
statistically
significant
additionally
trial
powered
disease
cohorts
consistent
trend
efficacy
across
new
onset
relapsing
refractory
cohorts
primary
efficacy
endpoint
adjudicated
gca
flare
week
treated
patients
hazard
ratio
secondary
efficacy
endpoint
sustained
remission
week
treated
patients
statistically
significant
additionally
trial
powered
disease
cohorts
consistent
trend
efficacy
across
new
onset
relapsing
refractory
cohorts
kiniksa
expects
data
global
phase
clinical
trial
mavrilimumab
gca
presented
abstracts
session
american
college
rheumatology
acr
convergence
maria
cid
hospital
clínic
university
barcelona
idibaps
investigator
trial
deliver
virtual
presentation
entitled
mavrilimumab
anti
receptor
α
monoclonal
antibody
reduces
risk
flare
increases
sustained
remission
phase
trial
patients
giant
cell
arteritis
monday
november
eastern
time
maria
cid
hospital
clínic
university
barcelona
idibaps
investigator
trial
deliver
virtual
presentation
entitled
mavrilimumab
anti
receptor
α
monoclonal
antibody
reduces
risk
flare
increases
sustained
remission
phase
trial
patients
giant
cell
arteritis
monday
november
eastern
time
kiniksa
announced
fda
granted
orphan
drug
designation
mavrilimumab
treatment
gca
kiniksa
evaluating
mavrilimumab
severe
pneumonia
hyperinflammation
enrolling
phase
portion
global
randomized
adaptive
design
phase
clinical
trial
additionally
data
expected
randomized
study
fourth
quarter
kiniksa
disclosed
discontinuation
clinical
collaboration
kite
gilead
company
evaluating
mavrilimumab
combination
axicabtagene
ciloleucel
relapsed
refractory
large
lymphoma
due
portfolio
strategy
review
kite
impacted
planned
trial
vixarelimab
monoclonal
antibody
inhibitor
signaling
osmrβ
data
phase
clinical
trial
vixarelimab
prurigo
nodularis
presented
european
academy
dermatology
venereology
eadv
virtual
congress
howard
sofen
md
david
geffen
ucla
school
medicine
delivered
virtual
presentation
entitled
vixarelimab
reduced
pruritus
improved
nodules
patients
prurigo
nodularis
phase
randomized
study
howard
sofen
md
david
geffen
ucla
school
medicine
delivered
virtual
presentation
entitled
vixarelimab
reduced
pruritus
improved
nodules
patients
prurigo
nodularis
phase
randomized
study
kiniksa
expects
initiate
phase
clinical
trial
vixarelimab
prurigo
nodularis
fourth
quarter
monoclonal
antibody
inhibitor
interaction
kiniksa
today
announced
cohorts
phase
clinical
trial
healthy
volunteers
dosed
dose
escalations
occurred
per
protocol
dose
limiting
safety
findings
data
support
continued
clinical
development
study
divided
two
parts
single
doses
mg
kg
mg
kg
mg
kg
mg
kg
mg
kg
intravenous
iv
single
doses
mg
kg
mg
kg
subcutaneous
pharmacokinetic
receptor
occupancy
dependent
antibody
response
data
first
cohorts
including
mg
kg
iv
dose
level
expected
fourth
quarter
final
data
safety
cohorts
expected
first
half
study
divided
two
parts
single
doses
mg
kg
mg
kg
mg
kg
mg
kg
mg
kg
intravenous
iv
single
doses
mg
kg
mg
kg
subcutaneous
pharmacokinetic
receptor
occupancy
dependent
antibody
response
data
first
cohorts
including
mg
kg
iv
dose
level
expected
fourth
quarter
final
data
safety
cohorts
expected
first
half
ligand
interaction
implicated
diseases
rheumatoid
arthritis
sjogren
syndrome
graves
disease
systemic
lupus
erythematosus
solid
organ
transplant
external
previously
demonstrated
corporate
activity
july
kiniksa
completed
public
offering
class
common
shares
public
offering
price
per
share
concurrent
public
offering
kiniksa
sold
class
common
shares
certain
existing
shareholders
affiliated
certain
kiniksa
directors
sale
price
equal
price
public
offering
aggregate
net
proceeds
kiniksa
offerings
deducting
underwriting
discounts
commissions
private
placement
fees
offering
costs
approximately
million
financial
results
third
quarter
kiniksa
reported
net
loss
million
compared
net
loss
million
third
quarter
total
operating
expenses
third
quarter
totaled
million
compared
million
third
quarter
compensation
expense
totaled
million
third
quarter
compared
million
third
quarter
september
company
cash
cash
equivalents
investments
million
debt
financial
guidance
kiniksa
expects
cash
cash
equivalents
investments
fund
current
operating
plan
kiniksa
kiniksa
biopharmaceutical
company
focused
discovering
acquiring
developing
commercializing
therapeutic
medicines
patients
suffering
debilitating
diseases
significant
unmet
medical
need
kiniksa
product
candidates
rilonacept
mavrilimumab
vixarelimab
based
strong
biologic
rationale
validated
mechanisms
target
underserved
conditions
offer
potential
differentiation
pipeline
assets
designed
modulate
immunological
pathways
across
spectrum
diseases
information
please
visit
rilonacept
rilonacept
weekly
recombinant
fusion
protein
blocks
alpha
beta
rilonacept
discovered
developed
regeneron
approved
fda
brand
name
treatment
periodic
syndromes
caps
specifically
familial
cold
autoinflammatory
syndrome
syndrome
rilonacept
treatment
deficiency
receptor
antagonist
dira
currently
pending
fda
approval
following
submission
supplemental
biologics
license
application
sbla
june
rilonacept
recurrent
pericarditis
investigational
drug
fda
granted
breakthrough
therapy
designation
rilonacept
treatment
recurrent
pericarditis
orphan
drug
designation
rilonacept
treatment
pericarditis
important
information
rilonacept
injection
blockade
may
interfere
immune
response
infections
serious
infections
reported
patients
taking
arcalyst
arcalyst
discontinued
patient
develops
serious
infection
taking
arcalyst
tnf
inhibitors
recommended
may
increase
risk
serious
infections
patients
receive
live
vaccine
taking
arcalyst
recommended
prior
initiation
therapy
arcalyst
patients
receive
recommended
vaccinations
appropriate
including
pneumococcal
vaccine
inactivated
influenza
vaccine
initial
development
program
arcalyst
six
serious
adverse
reactions
reported
four
patients
mycobacterium
intracellular
infection
gastrointestinal
bleeding
colitis
sinusitis
bronchitis
streptococcus
pneumoniae
meningitis
commonly
reported
adverse
reactions
associated
arcalyst
injection
site
reaction
upper
respiratory
tract
infection
patients
monitored
changes
lipid
profiles
provided
medical
treatment
warranted
treatment
immunosuppressants
including
arcalyst
may
result
increase
risk
malignancies
hypersensitivity
reactions
associated
arcalyst
administration
clinical
studies
rare
hypersensitivity
reaction
occurs
administration
arcalyst
discontinued
appropriate
therapy
initiated
mavrilimumab
mavrilimumab
investigational
monoclonal
antibody
targets
granulocyte
macrophage
colony
stimulating
factor
receptor
alpha
mavrilimumab
dosed
patients
rheumatoid
arthritis
phase
clinical
studies
europe
achieved
primary
endpoints
efficacy
safety
kiniksa
lead
indication
mavrilimumab
gca
rare
inflammatory
disease
arteries
kiniksa
also
evaluating
mavrilimumab
pneumonia
hyperinflammation
fda
granted
orphan
drug
designation
mavrilimumab
treatment
gca
vixarelimab
vixarelimab
investigational
monoclonal
antibody
targets
oncostatin
receptor
beta
osmrβ
mediates
signaling
oncostatin
osm
two
key
cytokines
implicated
pruritus
inflammation
fibrosis
kiniksa
believes
vixarelimab
monoclonal
antibody
development
targets
pathways
simultaneously
kiniksa
lead
indication
vixarelimab
prurigo
nodularis
chronic
inflammatory
skin
condition
investigational
humanized
monoclonal
antibody
designed
inhibit
interaction
key
signal
critical
maturation
immunoglobulin
class
switching
kiniksa
believes
disrupting
interaction
attractive
approach
blocking
mediated
driven
responses
drivers
multiple
autoimmune
disease
pathologies
rheumatoid
arthritis
sjogren
syndrome
graves
disease
systemic
lupus
erythematosus
solid
organ
transplant
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
cases
identify
forward
looking
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplate
believe
estimate
predict
potential
continue
negative
terms
similar
expressions
although
forwardlooking
statements
contain
identifying
words
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
plans
timing
clinical
trial
data
readouts
beliefs
research
clinical
trial
data
supporting
continued
clinical
development
anticipated
timing
potential
commercial
launch
rilonacept
recurrent
pericarditis
approved
fda
priority
review
planned
clinical
trials
timing
thereof
including
potential
phase
clinical
trial
vixarelimab
prurigo
nodularis
regulatory
milestones
related
payments
license
agreement
regeneron
upon
achievement
certain
specified
events
beliefs
potential
bring
rilonacept
potential
treatment
option
patients
recurrent
pericarditis
beliefs
mechanisms
action
product
candidates
potential
impact
approach
projected
timeframe
funding
current
operating
plan
current
cash
cash
equivalents
investments
statements
based
management
current
plans
estimates
expectations
statements
neither
promises
guarantees
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
including
without
limitation
following
delays
difficulty
enrollment
patients
activation
continuation
sites
clinical
trials
potential
complications
coordinating
among
requirements
regulations
guidelines
regulatory
authorities
across
number
jurisdictions
global
clinical
trials
potential
amendments
clinical
trial
protocols
initiated
us
required
regulatory
authorities
delays
difficulty
completing
clinical
trials
including
result
pandemic
potential
low
accrual
events
clinical
trials
potential
undesirable
side
effects
caused
product
candidates
potential
inability
demonstrate
safety
efficacy
satisfaction
applicable
regulatory
authorities
otherwise
producing
negative
inconclusive
commercially
uncompetitive
results
potential
applicable
regulatory
authorities
accept
bla
sbla
filings
delay
deny
approval
product
candidates
require
additional
trials
support
approval
potential
changes
final
data
preliminary
interim
data
clinical
trials
conducted
us
third
parties
including
investigator
initiated
studies
impact
additional
data
us
companies
potential
inability
replicate
later
clinical
trials
positive
results
earlier
clinical
trials
studies
product
candidates
potential
subsequent
clinical
trials
conducted
us
third
parties
including
studies
drug
substance
drug
product
shortages
reliance
third
parties
sole
source
supply
drug
substance
drug
products
used
product
candidates
reliance
third
parties
conduct
research
studies
clinical
trials
trials
product
candidates
substantial
existing
new
competition
impact
pandemic
measures
taken
response
pandemic
business
operations
well
business
operations
manufacturers
cros
upon
rely
conduct
clinical
trials
third
parties
conduct
business
otherwise
engage
including
fda
regulatory
authorities
changes
operating
plan
funding
requirements
ability
attract
retain
qualified
personnel
important
factors
discussed
caption
risk
factors
quarterly
report
form
filed
securities
exchange
commission
sec
august
reports
subsequently
filed
sec
could
cause
actual
results
differ
materially
indicated
statements
made
press
release
statements
represent
management
plans
estimates
expectations
date
press
release
may
elect
update
statements
point
future
disclaim
obligation
even
subsequent
events
cause
views
change
statements
relied
upon
representing
views
date
subsequent
date
press
release
registered
trademark
regeneron
pharmaceuticals
registered
trademark
gilead
sciences
related
companies
every
second
counts
kiniksa
investor
media
contact
mark
ragosa
mragosa
kiniksa
pharmaceuticals
consolidated
statements
operations
thousands
except
share
per
share
amounts
unaudited
three
months
ended
nine
months
ended
september
september
operating
expenses
research
development
general
administrative
total
operating
expenses
loss
operations
interest
income
loss
benefit
provision
income
taxes
benefit
provision
income
taxes
net
loss
net
loss
per
share
attributable
common
shareholders
diluted
weighted
average
common
shares
diluted
